Two FDA Warning Letters September 2025 and February 2026 The FDA issued formal warning letters to FitRX LLC, doing business as Zealthy, in September 2025 and again on February 20, 2026
Graphical Abstract Keywords Metabolic dysfunction-associated steatotic liver disease, Glucagon-like peptide-1 receptor agonist, Clinical trial, Treatment, Metabolic dysfunction-associated steatohepatitis, Fibrosis Introduction Nonalcoholic fatty liver disease has been used to describe hepatic steatosis without significant alcohol intake
Oxidative Stress Reduction Oxidative stress in the scalp refers to excess free radicals that damage follicle cells and can worsen androgendriven hair loss
Once central sensitization develops, even removing the original trigger may not immediately resolve the pain, because the amplification occurs in the central nervous system rather than at the periphery